Roche gets priority review for first one-time, single-dose flu drug in the U.S.

The Roche subsidiary Genentech and its baloxavir marboxil treatment could be first oral, single-dose antiviral and the first medicine with a novel proposed mechanism of action to treat the flu in nearly 20 years

Source: PharmaManufacturing.com - June 26, 2018 Category: Pharmaceuticals Source Type: news